Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995262 | 1.00 | CTSS (0.49) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL995261 | 1.00 | CTSS (0.49) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL995260 | 1.00 | CTSS (0.49) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL995820 | 0.99 | CTSS (0.49) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL995821 | 0.99 | CTSS (0.49) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL995822 | 0.99 | CTSS (0.49) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL8250516 | 0.99 | CTSS (0.49) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL12362385 | 0.94 | CTSS (0.48) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL996328 | 0.94 | CTSS (0.48) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL996326 | 0.94 | CTSS (0.48) | CTSSADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008251-B2 | Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-30 | — | — | US | disclosed |
| US-8008251-B2 | Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-30 | — | — | US | disclosed |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | HAVCR2, HCCS, CYP7A1 | CTSS 835/4885ADRB3 3034/4885ADRA2B 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.